Hmdb loader
Record Information
Version5.0
StatusPredicted
Creation Date2021-09-12 15:10:07 UTC
Update Date2022-11-30 19:57:18 UTC
HMDB IDHMDB0268732
Secondary Accession NumbersNone
Metabolite Identification
Common NamePG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/16:1(9Z))
DescriptionPG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/16:1(9Z)) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396 ). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/16:1(9Z)), in particular, consists of one chain of one 5(S),15(S)-Dihydroxyeicosatetraenoyl at the C-1 position and one chain of 9Z-hexadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396 ). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396 ). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396 ).
Structure
Thumb
Synonyms
ValueSource
[(2R)-3-{[(5R,8Z,11Z,13E,15S)-5,15-dihydroxyicosa-6,8,11,13-tetraenoyl]oxy}-2-[(9Z)-hexadec-9-enoyloxy]propoxy][(2S)-2,3-dihydroxypropoxy]phosphinateGenerator
Chemical FormulaC42H73O12P
Average Molecular Weight801.008
Monoisotopic Molecular Weight800.483964789
IUPAC Name[(2R)-3-{[(5R,6E,8Z,11Z,13E,15S)-5,15-dihydroxyicosa-6,8,11,13-tetraenoyl]oxy}-2-[(9Z)-hexadec-9-enoyloxy]propoxy][(2S)-2,3-dihydroxypropoxy]phosphinic acid
Traditional Name(2R)-3-{[(5R,6E,8Z,11Z,13E,15S)-5,15-dihydroxyicosa-6,8,11,13-tetraenoyl]oxy}-2-[(9Z)-hexadec-9-enoyloxy]propoxy((2S)-2,3-dihydroxypropoxy)phosphinic acid
CAS Registry NumberNot Available
SMILES
[H][C@](O)(CO)COP(O)(=O)OC[C@@]([H])(COC(=O)CCC[C@@H](O)\C=C\C=C/C\C=C/C=C/[C@@H](O)CCCCC)OC(=O)CCCCCCC\C=C/CCCCCC
InChI Identifier
InChI=1S/C42H73O12P/c1-3-5-7-8-9-10-11-12-13-14-18-21-25-31-42(48)54-40(36-53-55(49,50)52-34-39(46)33-43)35-51-41(47)32-26-30-38(45)29-24-20-17-15-16-19-23-28-37(44)27-22-6-4-2/h10-11,16-17,19-20,23-24,28-29,37-40,43-46H,3-9,12-15,18,21-22,25-27,30-36H2,1-2H3,(H,49,50)/b11-10-,19-16-,20-17-,28-23+,29-24+/t37-,38-,39-,40+/m0/s1
InChI KeyARUNSUCCSUMMDK-ATIILFCESA-N
Chemical Taxonomy
ClassificationNot classified
Ontology
Physiological effectNot Available
DispositionNot Available
ProcessNot Available
RoleNot Available
Physical Properties
StateNot Available
Experimental Molecular Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water SolubilityNot AvailableNot Available
LogPNot AvailableNot Available
Experimental Chromatographic PropertiesNot Available
Predicted Molecular Properties
PropertyValueSource
logP6.3ALOGPS
logP8.44ChemAxon
logS-6.4ALOGPS
pKa (Strongest Acidic)1.89ChemAxon
pKa (Strongest Basic)-1.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area189.28 ŲChemAxon
Rotatable Bond Count39ChemAxon
Refractivity222.33 m³·mol⁻¹ChemAxon
Polarizability91.59 ųChemAxon
Number of Rings0ChemAxon
BioavailabilityNoChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted Chromatographic Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
AllCCS[M+H]+287.12332859911
AllCCS[M+H-H2O]+287.04832859911
AllCCS[M+Na]+287.16132859911
AllCCS[M+NH4]+287.15832859911
AllCCS[M-H]-283.22132859911
AllCCS[M+Na-2H]-290.14132859911
AllCCS[M+HCOO]-297.75232859911
DeepCCS[M+H]+288.38130932474
DeepCCS[M-H]-286.48530932474
DeepCCS[M-2H]-319.99130932474
DeepCCS[M+Na]+294.15930932474

Predicted Kovats Retention Indices

Underivatized

MetaboliteSMILESKovats RI ValueColumn TypeReference
PG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/16:1(9Z))[H][C@](O)(CO)COP(O)(=O)OC[C@@]([H])(COC(=O)CCC[C@@H](O)\C=C\C=C/C\C=C/C=C/[C@@H](O)CCCCC)OC(=O)CCCCCCC\C=C/CCCCCC5934.2Standard polar33892256
PG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/16:1(9Z))[H][C@](O)(CO)COP(O)(=O)OC[C@@]([H])(COC(=O)CCC[C@@H](O)\C=C\C=C/C\C=C/C=C/[C@@H](O)CCCCC)OC(=O)CCCCCCC\C=C/CCCCCC4543.6Standard non polar33892256
PG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/16:1(9Z))[H][C@](O)(CO)COP(O)(=O)OC[C@@]([H])(COC(=O)CCC[C@@H](O)\C=C\C=C/C\C=C/C=C/[C@@H](O)CCCCC)OC(=O)CCCCCCC\C=C/CCCCCC5877.0Semi standard non polar33892256
Spectra

GC-MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted GC-MSPredicted GC-MS Spectrum - PG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/16:1(9Z)) GC-MS (TMS_1_1) - 70eV, PositiveNot Available2021-11-05Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - PG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/16:1(9Z)) GC-MS (TMS_1_2) - 70eV, PositiveNot Available2021-11-05Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - PG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/16:1(9Z)) GC-MS (TMS_1_3) - 70eV, PositiveNot Available2021-11-05Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - PG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/16:1(9Z)) GC-MS (TMS_1_4) - 70eV, PositiveNot Available2021-11-05Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - PG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/16:1(9Z)) GC-MS (TMS_1_5) - 70eV, PositiveNot Available2021-11-05Wishart LabView Spectrum

MS/MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - PG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/16:1(9Z)) 10V, Negative-QTOFsplash10-0002-0000000900-dfbd82bea5f62f6f9bf72021-09-28Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - PG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/16:1(9Z)) 20V, Negative-QTOFsplash10-0ue2-0179320700-08ecbac6c1c22b314f922021-09-28Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - PG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/16:1(9Z)) 40V, Negative-QTOFsplash10-0ue2-0279320700-5afe1100891cd5e739662021-09-28Wishart LabView Spectrum
Biological Properties
Cellular LocationsNot Available
Biospecimen LocationsNot Available
Tissue LocationsNot Available
Pathways
Normal Concentrations
Not Available
Abnormal Concentrations
Not Available
Associated Disorders and Diseases
Disease ReferencesNone
Associated OMIM IDsNone
DrugBank IDNot Available
Phenol Explorer Compound IDNot Available
FooDB IDNot Available
KNApSAcK IDNot Available
Chemspider IDNot Available
KEGG Compound IDNot Available
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkNot Available
METLIN IDNot Available
PubChem CompoundNot Available
PDB IDNot Available
ChEBI IDNot Available
Food Biomarker OntologyNot Available
VMH IDNot Available
MarkerDB IDNot Available
Good Scents IDNot Available
References
Synthesis ReferenceNot Available
Material Safety Data Sheet (MSDS)Not Available
General References
  1. Hajeyah AA, Griffiths WJ, Wang Y, Finch AJ, O'Donnell VB: The Biosynthesis of Enzymatically Oxidized Lipids. Front Endocrinol (Lausanne). 2020 Nov 19;11:591819. doi: 10.3389/fendo.2020.591819. eCollection 2020. [PubMed:33329396 ]